KR920019781A - 벤즈이미다졸류로부터 유도된 항진정 항히스타민제 - Google Patents
벤즈이미다졸류로부터 유도된 항진정 항히스타민제 Download PDFInfo
- Publication number
- KR920019781A KR920019781A KR1019920005583A KR920005583A KR920019781A KR 920019781 A KR920019781 A KR 920019781A KR 1019920005583 A KR1019920005583 A KR 1019920005583A KR 920005583 A KR920005583 A KR 920005583A KR 920019781 A KR920019781 A KR 920019781A
- Authority
- KR
- South Korea
- Prior art keywords
- general formula
- radical
- benzimidazole
- ethoxyethyl
- butyl
- Prior art date
Links
- 229940125715 antihistaminic agent Drugs 0.000 title claims 2
- 239000000739 antihistaminic agent Substances 0.000 title claims 2
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000000932 sedative agent Substances 0.000 title 1
- -1 alkyl radical Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000005905 mesyloxy group Chemical group 0.000 claims 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims 2
- RHXWRGKDHVRNPZ-UHFFFAOYSA-N 1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)-1,4-diazepan-1-yl]methyl]benzimidazole Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1CN(CC1)CCCN1CCCCN1C=CC=N1 RHXWRGKDHVRNPZ-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 일반식(I)의 화합물인 것을 특징으로 하는 벤즈이미다졸로부터 유도된 새로운 유도체 및 그의 치료학적으로 수용가능한 염.상기식에서 -R1및 R2는 동일하거나 다를수 있으며, 수소 또는 할로겐 원자, 저급 알킬 라디칼, 히드록실, 라디칼, 알콕시 라디칼, 알킬카르복실산염 라디칼, 또는 아릴 또는 치환된 아릴 라디칼을 나타내고, -n은 0 또는 1의 값을 갖고, -m은 2내지 4의 값을 가지며, -X,Y,Z 및 W는 동일하거나 다를 수 있으며, 또다른 방향족 또는 비방향족 고리의 일부분을 나타낼 수도 있고, 수소나 할로겐 원자 또는 또다른 알킬, 아릴, 카르복시알킬, 카르복실릭, 히드록실, 알킬 히드록실, 설포닉 및 알킬설포닉 라디칼에 연결된 질소원자 또는 탄소원자를 나타낸다.
- 제1항에 있어서, 하기의 군으로 부터 선택되는 일반식(I)의 화합물.1-(2-에톡시에틸)-2-｛4-〔4-(피라졸-1-일)부틸〕-호모피페라진-1-일-메틸｝벤즈이미다졸 1-(2-에톡시에틸)-2-｛4-〔4-(4,5-디클로로-2-이미다졸-1-일)부틸〕-호모피페라진-1-일｝벤즈이미다졸 1-(2-에톡시에틸)-2-｛4-〔4-(피라졸-1-일)부틸〕-호모피페라진-1-일-메틸｝벤즈이미다졸 1-(2-에톡시에틸)-2-｛4-〔4-(4-카르복시피라졸-1-일)부틸〕-호모피페라진-1｝벤즈이미다졸 1-(2-에톡시에틸)-2-｛4-〔4-(4-에틸옥시카르보닐-피라졸-1-일)부틸〕-호모피페라진-1｝벤즈이미다졸
- 제1항 또는 제2항에 있어서, 다음의 공정중 적어도 하나를 수행하는 것을 특징으로 하는 상기 화합물의 제조방법.3a)하기 일반식(Ⅱa)또는 선택적으로 하기 일반식(Ⅱb)와 하기 일반식(Ⅲ)과의 반응.상기식에서, R1, R2, n 및 m은 상기와 같은 의미를 가지며, A는 할로겐원자 또는 토실옥시나 메실옥시로부터 선택되는 양호한 이탈기를 나타낸다.상기식에서,X, Y, Z 및 W는 상술한 바와 같다.3b)A가 -NH2라디칼을 나타내는 상기 일반식(Ⅱa)와 2,5-디 메톡시테트라하이드로퓨란과의 반응, 3c)하기 일반식(Ⅳ)의 화합물과 하기 일반식(Ⅴ)이 화합물과의 반응.상기식에서, R1, R2, n은 상술한 바와 같은 의미를 가진다.상기식에서,X, Y, Z, W 및 m은 상술한 바와 같으며.B는 할로겐원자 또는 토실옥시나 메실옥시로부터 선택되는 양호한 이탈기를 나타낸다.
- 의약품, 특히 항히스타민제로 사용되는 의약품으로서 제1항 또는 제2항에 따른 일반식(I)의 유도체 및 그의 치료학적으로 수용가능한 염.
- 제약학적으로 수용가능한 캐리어에 부가하여 제1항 또는 제2항에 따른 일반식(I)의 유도체 또는 그들의 생체학적으로 수용가능한 염증의 적어도 하나를 포함하는 것을 특징으로 하는 제약학적 조성물.
- 제1항 또는 제2항에 따른 일반식(I)의 유도체 및 그 생체학적으로 수용가능한 염의, 히스타민에 의하여 야기되는 다양한 과민성 질환의 예방 및 치료를 위한 의약품의 제조에의 이용.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9104171A FR2674856B1 (fr) | 1991-04-05 | 1991-04-05 | Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments. |
| FR9104171 | 1991-04-05 | ||
| FR91/04171 | 1991-04-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR920019781A true KR920019781A (ko) | 1992-11-20 |
| KR970011298B1 KR970011298B1 (ko) | 1997-07-09 |
Family
ID=9411523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920005583A KR970011298B1 (ko) | 1991-04-05 | 1992-04-03 | 벤즈이미다졸류로부터 유도된 무진정성 항히스타민제 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5214040A (ko) |
| EP (1) | EP0507696B1 (ko) |
| JP (1) | JP3060054B2 (ko) |
| KR (1) | KR970011298B1 (ko) |
| CN (1) | CN1028367C (ko) |
| AT (1) | ATE126228T1 (ko) |
| AU (1) | AU647904B2 (ko) |
| BG (1) | BG60678B1 (ko) |
| BR (1) | BR1100983A (ko) |
| CA (1) | CA2065061A1 (ko) |
| CZ (1) | CZ279506B6 (ko) |
| DE (1) | DE69203911T2 (ko) |
| DK (1) | DK0507696T3 (ko) |
| ES (1) | ES2046110B1 (ko) |
| FI (1) | FI99112C (ko) |
| FR (1) | FR2674856B1 (ko) |
| GR (1) | GR3017643T3 (ko) |
| HU (1) | HU214316B (ko) |
| IL (1) | IL101483A (ko) |
| IS (1) | IS1639B (ko) |
| MX (1) | MX9201556A (ko) |
| NO (1) | NO179552C (ko) |
| NZ (1) | NZ242208A (ko) |
| PL (1) | PL167720B1 (ko) |
| RO (1) | RO109198B1 (ko) |
| RU (1) | RU2099336C1 (ko) |
| TW (1) | TW208003B (ko) |
| YU (1) | YU48826B (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264456B1 (it) * | 1993-05-14 | 1996-09-23 | Dompe Farmaceutici Spa | Derivati del 2-(benzimidazol-2-il)-1,3-diaminopropano farmacologicamente attivi. |
| FR2727865B1 (fr) * | 1994-12-08 | 1997-07-18 | Esteve Labor Dr | Utilisation des derives de 2-(4-(azolybutyl)-piperazinyl- (methyl))-benzimidazole et analogues ainsi que de leurs sels, pour la preparation de medicaments destines au traitement ou a la prophylaxie de l'asthme |
| US5773616A (en) * | 1995-02-15 | 1998-06-30 | Neurogen Corporation | Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands |
| WO1996025411A1 (en) * | 1995-02-15 | 1996-08-22 | Neurogen Corporation | Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands |
| FR2731618B1 (fr) * | 1995-03-14 | 1997-08-01 | Esteve Labor Dr | Composition ophtalmique topique comprenant un derive de 2-(4-(azolylbutyl)-piperazinyl-methyl)-benzimidazole, notamment pour le traitement de la conjonctivite allergique |
| US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
| US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
| US5998439A (en) | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
| US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
| TWI225488B (en) * | 1999-12-21 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivatives of homopiperidinyl substituted benzimidazole analogues |
| NZ520402A (en) * | 2000-01-19 | 2006-04-28 | Cadila Healthcare Ltd | Novel compounds having hypolipedemic, hypocholesteremic activites, process for their preparation and pharmaceutical compositions containing them |
| HUP0301550A2 (hu) * | 2000-10-31 | 2003-09-29 | Basf Aktiengesellschaft | Hiper-elágazó poliuretánok alkalmazása nyomdafestékek elżállítására |
| JP2005532991A (ja) * | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ |
| CN101089000B (zh) | 2006-06-16 | 2011-01-05 | 北京大学 | 螺环哌嗪季铵盐类化合物及其制备方法和应用 |
| RU2533825C2 (ru) * | 2009-06-11 | 2014-11-20 | Сиена Байотек С.П.А. | ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА И ИМИДАЗО[4,5-с]ПИРИДИНА, В КАЧЕСТВЕ АНТАГОНИСТА ПУТИ HEDGEHOG |
| LT2938597T (lt) * | 2012-12-27 | 2017-01-25 | Alzprotect | N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas |
| KR102057075B1 (ko) * | 2018-11-30 | 2019-12-19 | 우승열 | 페트병에 장착되는 여과장치 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
| DE3336409A1 (de) * | 1983-10-06 | 1985-04-18 | Ludwig Heumann & Co GmbH, 8500 Nürnberg | Chinazolinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5010075A (en) * | 1987-04-24 | 1991-04-23 | Syntex Pharmaceuticals Ltd. | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives |
| CA1317939C (en) * | 1987-07-01 | 1993-05-18 | Janssen Pharmaceutica Naamloze Vennootschap | ¬(bicyclic heterocyclyl)methyl and -hetero| substituted hexahydro-1h-azepines and pyrrolidines |
| FR2665161B1 (fr) * | 1990-07-26 | 1992-11-27 | Esteve Labor Dr | Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments. |
-
1991
- 1991-04-05 FR FR9104171A patent/FR2674856B1/fr not_active Expired - Fee Related
-
1992
- 1992-03-31 YU YU33692A patent/YU48826B/sh unknown
- 1992-03-31 TW TW081102419A patent/TW208003B/zh active
- 1992-04-01 RU SU925011426A patent/RU2099336C1/ru active
- 1992-04-02 NZ NZ242208A patent/NZ242208A/en unknown
- 1992-04-02 RO RO92-200447A patent/RO109198B1/ro unknown
- 1992-04-02 AU AU13979/92A patent/AU647904B2/en not_active Ceased
- 1992-04-02 IS IS3832A patent/IS1639B/is unknown
- 1992-04-03 FI FI921473A patent/FI99112C/fi active
- 1992-04-03 ES ES09200813A patent/ES2046110B1/es not_active Expired - Lifetime
- 1992-04-03 IL IL10148392A patent/IL101483A/en not_active IP Right Cessation
- 1992-04-03 PL PL92294101A patent/PL167720B1/pl unknown
- 1992-04-03 EP EP92400940A patent/EP0507696B1/fr not_active Expired - Lifetime
- 1992-04-03 HU HU9201145A patent/HU214316B/hu not_active IP Right Cessation
- 1992-04-03 US US07/863,208 patent/US5214040A/en not_active Expired - Fee Related
- 1992-04-03 KR KR1019920005583A patent/KR970011298B1/ko not_active IP Right Cessation
- 1992-04-03 BG BG96180A patent/BG60678B1/bg unknown
- 1992-04-03 CZ CS921017A patent/CZ279506B6/cs not_active IP Right Cessation
- 1992-04-03 DE DE69203911T patent/DE69203911T2/de not_active Expired - Fee Related
- 1992-04-03 NO NO921315A patent/NO179552C/no not_active IP Right Cessation
- 1992-04-03 DK DK92400940.0T patent/DK0507696T3/da active
- 1992-04-03 AT AT92400940T patent/ATE126228T1/de not_active IP Right Cessation
- 1992-04-03 CA CA002065061A patent/CA2065061A1/fr not_active Abandoned
- 1992-04-03 MX MX9201556A patent/MX9201556A/es unknown
- 1992-04-04 CN CN92102353A patent/CN1028367C/zh not_active Expired - Fee Related
- 1992-04-06 JP JP4084230A patent/JP3060054B2/ja not_active Expired - Lifetime
-
1995
- 1995-10-04 GR GR950402756T patent/GR3017643T3/el unknown
-
1997
- 1997-05-14 BR BR1100983-7A patent/BR1100983A/pt active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920019781A (ko) | 벤즈이미다졸류로부터 유도된 항진정 항히스타민제 | |
| HU207796B (en) | Process for producing pharmaceutical compositions containing imidazol derivatives of antinociceptive activity | |
| KR920014804A (ko) | 아릴 (또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용 | |
| KR970702251A (ko) | 허혈성 질환에 기인하는 증상의 개선 또는 치료약 및 이에 유용한 화합물(Ameliorant or0 remedy for symptoms caused by ischemic diseases and compounds useful therefor) | |
| KR940021063A (ko) | 퀴놀론카르복실산 유도체, 이의 제조방법 및 용도 | |
| KR920002587A (ko) | 벤즈이미다졸 유도체, 그 제조방법 및 의약물로의 이용 | |
| DK0453042T3 (da) | Hidtil ukendte 2 9-disubstituerede 4H-pyhrido[1 2-a]pyridin-4-oner | |
| KR930004262A (ko) | 메타노안트라센 화합물 | |
| KR920000755A (ko) | 축합 헤테로사이클릭 화합물 및 이를 함유하는 정신약제 조성물 | |
| ATE147625T1 (de) | Hydantoin- oder imidazolidintrionderivate zur vorbeugung oder behandlung von niereninsuffizienz | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| KR950032147A (ko) | 아실화된 아미노알칸이미다졸 및 -트리아졸 | |
| KR937000438A (ko) | 3-인돌릴 티오아세테이트 유도체 | |
| ATE286503T1 (de) | (hetero)aryl-sulfonamid derivate, deren herstellung und deren verwenddung als faktor xa inhibitoren | |
| MXPA02011464A (es) | Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1. | |
| KR900001691A (ko) | 피리다지논 유도체 | |
| KR880002828A (ko) | 디하이드로피리딘 유도체 및 이것의 약학적 조성말 | |
| KR920002517A (ko) | 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법 | |
| KR870005641A (ko) | 고혈압 치료용 조성물 | |
| KR870011105A (ko) | 1,3-치환된 이미다졸륨 염 | |
| NO20020804D0 (no) | Nye A-500359-derivater | |
| EP0485219A3 (en) | Medicaments for preventing and treating circulatory organ diseases containing spiro-3-heteroazolidine compounds | |
| DE69226931D1 (de) | Guanidinothiazolederivate und ihre Anwendung als H2-Rezeptor-Antagonisten | |
| KR900004717A (ko) | 이미다졸 부정맥증 치료제 | |
| KR930021629A (ko) | 피페라진 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20000711 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |